These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24292246)

  • 1. Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11.
    Nakano Y; Kobayashi T; Oshima F; Fukazawa E; Yamagami T; Shiraishi Y; Takanosu M
    J Vet Med Sci; 2014 Apr; 76(4):545-8. PubMed ID: 24292246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor.
    Nakano Y; Kobayashi M; Bonkobara M; Takanosu M
    Vet Immunol Immunopathol; 2017 Jun; 188():84-88. PubMed ID: 28615132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
    Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M
    Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.
    Rossi G; Bertani C; Mari S; Marini C; Renzoni G; Ogilvie G; Magi GE
    Vet Res Commun; 2013 Jun; 37(2):101-8. PubMed ID: 23315207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.
    Kobayashi M; Sugisaki O; Ishii N; Yamada O; Ito K; Kuroki S; Sasaki Y; Ono K; Washizu T; Bonkobara M
    Vet J; 2012 Jul; 193(1):264-7. PubMed ID: 22153896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.
    Isotani M; Yamada O; Lachowicz JL; Tamura K; Yagihara H; Fujino Y; Ono K; Washizu T; Bonkobara M
    Br J Haematol; 2010 Jan; 148(1):144-53. PubMed ID: 19804453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation.
    Hoffmann KM; Moser A; Lohse P; Winkler A; Binder B; Sovinz P; Lackner H; Schwinger W; Benesch M; Urban C
    Blood; 2008 Sep; 112(5):1655-7. PubMed ID: 18567837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mastocytosis: advances in diagnosis and treatment.
    Hungness SI; Akin C
    Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
    Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
    Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
    Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
    Zhang LY; Smith ML; Schultheis B; Fitzgibbon J; Lister TA; Melo JV; Cross NC; Cavenagh JD
    Leuk Res; 2006 Apr; 30(4):373-8. PubMed ID: 16183119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
    Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures].
    Kong M; Wang YL; Xu LJ; Teng XD
    Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):617-20. PubMed ID: 20079191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
    Debiec-Rychter M; Dumez H; Judson I; Wasag B; Verweij J; Brown M; Dimitrijevic S; Sciot R; Stul M; Vranck H; Scurr M; Hagemeijer A; van Glabbeke M; van Oosterom AT;
    Eur J Cancer; 2004 Mar; 40(5):689-95. PubMed ID: 15010069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of mutations in the c-kit gene of 32 dogs with mastocytoma.
    Riva F; Brizzola S; Stefanello D; Crema S; Turin L
    J Vet Diagn Invest; 2005 Jul; 17(4):385-8. PubMed ID: 16131001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
    Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
    Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.